Literature DB >> 10452806

Quantitation of 3,4-dihydroxyphenylacetaldehyde and 3, 4-dihydroxyphenylglycolaldehyde, the monoamine oxidase metabolites of dopamine and noradrenaline, in human tissues by microcolumn high-performance liquid chromatography.

W J Burke1, H D Chung, S W Li.   

Abstract

We recently described the chemical synthesis of 3, 4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde, the monamine oxidase metabolites of dopamine and noradrenaline, respectively. We demonstrated the neurotoxicity of these compounds. Catecholamine nerve cells which synthesize these aldehydes die in degenerative brain diseases, such as Parkinson's and Alzheimer's. Here we describe a sensitive method for separating these catecholaldehydes from catecholamines and their other oxidative and methylated metabolites by microcolumn high-performance liquid chromatography with electrochemical detection. We then quantitate catecholamines and their major metabolites in human brain, plasma, and urine. The method can be used to determine the role of these catecholaldehydes in human disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10452806     DOI: 10.1006/abio.1999.4196

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  9 in total

1.  Inactivation of glyceraldehyde-3-phosphate dehydrogenase by the dopamine metabolite, 3,4-dihydroxyphenylacetaldehyde.

Authors:  Brigitte C Vanle; Virginia R Florang; Daryl J Murry; Arturo L Aguirre; Jonathan A Doorn
Journal:  Biochem Biophys Res Commun       Date:  2017-08-19       Impact factor: 3.575

Review 2.  MPTP and SNpc DA neuronal vulnerability: role of dopamine, superoxide and nitric oxide in neurotoxicity. Minireview.

Authors:  V Jackson-Lewis; R J Smeyne
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

3.  L-threo-dihydroxyphenylserine corrects neurochemical abnormalities in a Menkes disease mouse model.

Authors:  Anthony Donsante; Patricia Sullivan; David S Goldstein; Lauren R Brinster; Stephen G Kaler
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

4.  Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol.

Authors:  Jennifer N Rees; Virginia R Florang; Laurie L Eckert; Jonathan A Doorn
Journal:  Chem Res Toxicol       Date:  2009-07       Impact factor: 3.739

Review 5.  Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders.

Authors:  David S Goldstein; Irwin J Kopin; Yehonatan Sharabi
Journal:  Pharmacol Ther       Date:  2014-06-16       Impact factor: 12.310

6.  The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis.

Authors:  W Michael Panneton; V B Kumar; Qi Gan; William J Burke; James E Galvin
Journal:  PLoS One       Date:  2010-12-13       Impact factor: 3.240

7.  Anti-VEGF Effect of Bioactive Indolic Compounds and Hydroxytyrosol Metabolites.

Authors:  Marta Gallardo-Fernández; Ana B Cerezo; Ruth Hornedo-Ortega; Ana M Troncoso; M Carmen Garcia-Parrilla
Journal:  Foods       Date:  2022-02-11

8.  Effect of ALDH2 on Sleep Disturbances in Patients with Parkinson's Disease.

Authors:  Chia-Yen Lin; Rwei-Ling Yu; Ruey-Meei Wu; Chun-Hsiang Tan
Journal:  Sci Rep       Date:  2019-12-12       Impact factor: 4.379

Review 9.  Delta-secretase cleavage of Tau mediates its pathology and propagation in Alzheimer's disease.

Authors:  Seong Su Kang; Eun Hee Ahn; Keqiang Ye
Journal:  Exp Mol Med       Date:  2020-08-28       Impact factor: 8.718

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.